Kitov
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Consensi™
    • NT-219
  • News
  • Investors
    • Welcome
    • Events
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Press Releases
    • Investor Alerts
    • Company Presentations
  • Contact Us
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Consensi™
    • NT-219
  • News
  • Investors
    • Welcome
    • Events
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Press Releases
    • Investor Alerts
    • Company Presentations
  • Contact Us
Kitov
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Consensi™
    • NT-219
  • News
  • Investors
    • Welcome
    • Events
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Press Releases
    • Investor Alerts
    • Company Presentations
  • Contact Us
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Consensi™
    • NT-219
  • News
  • Investors
    • Welcome
    • Events
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Press Releases
    • Investor Alerts
    • Company Presentations
  • Contact Us
Pipeline
Consensi™

Consensi™  is a combination drug that is indicated for the treatment of osteoarthritis (OA) pain and hypertension simultaneously. Consensi™ is comprised of two FDA-approved drugs, celecoxib (the active ingredient in Pfizer’s Celebrex®) for the treatment of pain caused by OA, and amlodipine besylate (the active ingredient in Pfizer’s Norvasc®), a drug designed to treat hypertension. 

 

In December 2015, Kitov announced that the Phase III clinical trial for Consensi™ successfully met its primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). The trial’s primary efficacy endpoint was to show that Consensi™ lowers daytime systolic blood pressure by at least 50% of that achieved in patients treated only with amlodipine. The trial data, in fact, revealed that Consensi™ was more efficacious at reducing blood pressure than when amlodipine was used on its own.

 

The trial data also showed that the favorable blood pressure effects of Consensi™ were present in all blood pressure variables measured in the study. Kitov determined that the blood pressure reduction synergy seen with combining celecoxib and amlodipine was present in daytime systolic blood pressure – the study’s primary efficacy endpoint. Based on the data, however, the blood pressure reduction synergy was also present with all other blood pressure variables and at all times of day – i.e. daytime diastolic blood pressure, nighttime systolic blood pressure, and nighttime diastolic blood pressure. Although celecoxib, when combined with amlodipine, appears to have a synergistic effect by lowering blood pressure, it lacks this effect when administered by itself.

 

These results not only confirm the study’s top-line findings, but also reveal that using a combination drug for treating pain can improve patient health.

 

Additional data from the Phase III clinical trial of Consensi™ suggested beneficial effects on renal (kidney) function. The data also suggested that Consensi™ may protect against the amlodipine side effect of causing fluid retention by the kidneys.

Therefore, Kitov conducted a Phase III/IV clinical trial in the second half of 2017. The trial’s top-line results, which were announced in October 2017, not only validated the top-line results of the Phase III trial, but also showed that Consensi™ improves renal function. 

Kitov submitted a New Drug Application (NDA) in July 2017. The U.S. Food & Drug Administration (FDA) filed the NDA in September 2017, thereby accepting it for a full review, and approved Consensi™ oral tablets for marketing on May 31, 2018.

Celebrex® is a registered trademark of G.D. Searle LLC (a subsidiary of Pfizer Inc.). Norvasc® is a registered trademark of Pfizer Inc.

latest news

Kitov Pharma Reports Year End 2018 Financial Results and Provides Business Update

On February 7, 2019

Kitov Announces Pricing of $6 Million Registered Direct Offering

On January 16, 2019

New Data on Kitov’s NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect

On January 15, 2019

Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis Pharmaceuticals

On January 3, 2019

Kitov to Present Data on NT219 in Combination with Keytruda® and Erbitux® at AACR International Cancer Immunotherapy Conference

On September 26, 2018
CONTACT US
CONTACT US
One Azrieli Center
Round Tower, Floor 19
132 Menachem Begin Road
Tel Aviv 670110 Israel

Tel. 972 3 9333121
Fax. 972 3 5097196
ir@kitovpharma.com

© 2018 Kitov Pharmaceuticals Ltd. All rights reserved.
Scroll to top